Medical/Pharmaceuticals
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology
SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, recently published the phase III study results of denosumab biosimilar (MW032) online in the international top journal of JAMA Oncology. This is the first recorded tria...
2024-02-21 22:00
1573
Zylox-Tonbridge Receives Marketing Approvals for Multiple Products in the UAE
HANGZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK), a medical device company specializing in peripheral and neurovascular interventions, proudly announces the recent marketing approvals granted by the Ministry of Health and Prevention in theUnited Arab Emirates for five of i...
2024-02-21 16:16
1343
Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets
OSAKA, Japan, Feb. 20, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. ( Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a research collaboration agreement with InveniAI® LLC (Guilford, Connecticut, USA; President and CEO: Krishnan Nandabalan; "Inveni...
2024-02-21 11:56
1401
Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology
CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors again...
2024-02-20 22:30
1701
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of B7-H3 targeting ADC (R&D code: 7MW3711) for advanced malignant solid tumor was approved by the U.S. Food and Drug Admi...
2024-02-20 22:00
1467
FDA Grants Orphan Drug Designation to 9MW3011
SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Orphan Drug Designation (ODD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (P...
2024-02-20 22:00
1499
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval fora solid tumor cancer. PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Admini...
2024-02-20 21:00
3348
Concord Medical Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
BEIJING, Feb. 20, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it has received a letter (the "Letter") from t...
2024-02-20 20:00
2896
Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)
HEFEI, China, Feb. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, autoimmune diseases, and inflammation, through targeted protein degradation technology, today announced th...
2024-02-20 20:00
1315
Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.
WUHAN, China and SAN DIEGO, Feb. 19, 2024 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today thatthe last patient has been enrolled in Phase I/II clinical trial of Opvika® (Esonadogene Imvoparvovec) for the treatment of Leber hereditary optic neuropathy caused byND4 mutati...
2024-02-19 19:30
1511
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor
BEIJING and SHANGHAI and BOSTON, Feb. 18, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received approval of registrational phase III clinical trial of the combination therapy between its novel KRAS G12C inhib...
2024-02-18 20:50
2543
China Medical University Hospital (CMUH) in Taiwan Upgrades Smart Healthcare with Gen AI
Establishing a comprehensive "AI-assisted Physician" using generative AI from Google Cloud, including MedLM TAICHUNG, Feb. 17, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH) inTaiwan announced its collaboration with Google Cloud in mid-December 2023. Using Google Cloud's generativ...
2024-02-17 21:30
5929
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC
- A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Checkpoint Inhibitor across multiple cancer types SEOUL, South Korea, Feb. ...
2024-02-16 22:03
5196
iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology
▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating CRISPR/Cas Technology BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.i...
2024-02-15 11:37
1597
STARmed to Accelerate Global Market Entry of EUSRA and ELRA Products through Olympus
SEOUL, South Korea, Feb. 14, 2024 /PRNewswire/ -- STARmed, a leading developer
and manufacturer of medical devices for tumor ablation, today announced global
market expansion of its EUSRA and ELRA products, throughOlympus
2024-02-14 22:00
1165
Sky Labs' CART BP Becomes the World's First to Complete Comparative Studies with All Blood Pressure Measurement Methods
- The only cuffless blood pressure monitor to complete comparative studies with three types of existing blood pressure measurement methods and prove even accuracy - 24-hour Ambulatory Blood Pressure Monitoring is the first pilot research to reflect ESH recommendations in 2023 SEOUL, South K...
2024-02-14 21:00
1662
YS Biopharma Announces Appointment of New Directors
GAITHERSBURG, Md., Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccin...
2024-02-14 20:50
3666
GC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024
* Recent updates on its development of LSD treatments were presented YONGIN, South Korea, Feb. 14, 2024 /PRNewswire/ -- GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced onFeb. 14th that it has presented the development updates on its LSD (Lysosomal Storage D...
2024-02-14 16:33
1844
PCA 500™-- the world's most efficient and versatile 12-lead ECG, receives FDA clearance for use in acute care
LOS ANGELES, Feb. 13, 2024 /PRNewswire/ -- QT Medical, a medtech company focusing on improving cardiac care with electrocardiogram (ECG or EKG), announces that it has received 510(k) clearance from the FDA for PCA 500™ use in acute care. PCA 500 was first 510(k) cleared in 2018 for professional a...
2024-02-14 00:30
1578
Datasea Reports Second Quarter Fiscal Year 2024 Financial Results and Operations Update - Second Quarter Revenue is $11.3 Million Versus $0.1 Million in the Year-Ago Period
BEIJING, Feb. 13, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a global technology company that develops and provides products utilizing intelligent acoustics including ultrasound, infrasound and directional sound, and provides 5G multimodal communication, upgrad...
2024-02-13 22:35
4028
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5216
